Nautilus Biotechnology, Inc. (NAUT)
| Market Cap | 329.07M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -59.00M |
| Shares Out | 126.56M |
| EPS (ttm) | -0.47 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 292,309 |
| Open | 2.770 |
| Previous Close | 2.570 |
| Day's Range | 2.460 - 2.818 |
| 52-Week Range | 0.620 - 4.310 |
| Beta | 0.99 |
| Analysts | Strong Buy |
| Price Target | 4.00 (+53.85%) |
| Earnings Date | Apr 28, 2026 |
About NAUT
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for NAUT stock is "Strong Buy" and the 12-month stock price target is $4.0.
News
Nautilus Biotechnology Earnings Call Transcript: Q1 2026
Q1 2026 saw strong execution on commercialization plans, reduced operating expenses, and expanded early access engagement, with Baylor College of Medicine as the first named EAP customer. Cash runway extends through 2027, and commercial launch remains on track for late 2026.
Nautilus Biotechnology Reports First Quarter 2026 Financial Results
SEATTLE, April 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the fir...
Nautilus Biotechnology Transcript: Investor Summit Virtual Conference
Proteomics remains a critical bottleneck in drug development, with current technologies lacking depth and reproducibility. Nautilus is introducing a disruptive platform with novel assays and a high-throughput instrument, aiming for broad market adoption and significant revenue ramp by mid-next year.
Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform
• Baylor selects the Nautilus Voyager™ Platform, now available through Early Access Program, for development of a first-in-class computational multi-omics toolkit • NIH-funded project leverages collab...
Nautilus Biotechnology Transcript: TD Cowen 46th Annual Health Care Conference
A novel proteomics platform was showcased, offering unprecedented sensitivity and reproducibility for both broadscale and targeted protein analysis. Early access programs are underway, with commercial launch and expanded assay portfolio expected by next year.
Nautilus Biotechnology Earnings Call Transcript: Q4 2025
Q4 2025 saw major technical and commercial milestones, including the Voyager instrument debut and early access program launch. Operating expenses and cash burn declined year-over-year, with commercial launch and revenue ramp expected in 2027.
Nautilus Biotechnology to Participate in the TD Cowen 46th Annual Health Care Conference
SEATTLE, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company wil...
Nautilus Biotechnology Reports Successful Installation and Testing of its First Field Evaluation Unit at the Buck Institute for Research on Aging
• Buck Institute's deployment of Nautilus' instrument generates tau proteoform data, providing external validation of the company's next-generation single-molecule proteomics platform • Joint researc...
Nautilus Biotechnology Earnings Call Transcript: Q3 2025
Q3 2025 saw major scientific advances, expanded collaborations, and disciplined expense management, with operating expenses down 19% year-over-year and a strong cash position. Early access for the Tau assay launches in H1 2026, with broad-scale launch targeted for late 2026.
Nautilus Biotechnology Transcript: Q3 Investor Summit Group Virtual Conference 2025
A new proteomics platform aims to revolutionize drug discovery by enabling comprehensive, high-precision protein analysis, addressing inefficiencies in current R&D and unlocking AI-driven biomedical advances. Commercial launch is planned for late 2026, with strong financial backing and leadership alignment.
Nautilus Biotechnology Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
A new proteomics platform is set to launch at the end of next year, aiming for comprehensive proteome analysis and high reproducibility, with initial applications in neurodegenerative disease. The company is prioritizing broad-scale discovery, maintaining strong financial discipline, and preparing for a $1 million bundled offering.
Nautilus Biotechnology to Participate in Upcoming September Investor Conferences
SEATTLE, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company wil...
Nautilus Biotechnology Earnings Call Transcript: Q2 2025
Q2 2025 saw a milestone with public validation of a unique proteoform platform, strong cross-sector interest, and two major research collaborations. Operating expenses and net loss declined year-over-year, with a robust cash position and a clear roadmap for product and revenue ramp in 2026–2027.
Nautilus Biotechnology Reports Second Quarter 2025 Financial Results
SEATTLE, July 31, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial resul...
Nautilus Biotechnology to Announce Second Quarter 2025 Financial Results on July 31, 2025
SEATTLE, July 15, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, to...
Nautilus Biotechnology Transcript: Goldman Sachs 46th Annual Global Healthcare Conference
A novel proteomics platform aims to deliver comprehensive protein analysis, addressing current limitations in mass spectrometry and enabling new discoveries in drug development and disease research. Commercial launch is planned for late 2026, with early access programs and targeted assays in 2025.
Nautilus Biotechnology Earnings Call Transcript: Q1 2025
Q1 2025 saw major progress in tau proteoform assay validation, strong customer interest, and ongoing partnership discussions. Operating expenses and net loss declined year-over-year, with a cash runway projected through 2027 and platform launch on track for late 2026.
Nautilus Biotechnology Transcript: TD Cowen 45th Annual Healthcare Conference
A novel proteomics platform aims to deliver near-complete protein analysis with single-molecule sensitivity, targeting pharma, diagnostics, and research markets. Commercial launch is delayed to late 2026 due to technical challenges, but early proteoform assays are progressing with pharma partnerships and minimal near-term revenue.
Nautilus Biotechnology layoffs 16% of workforce, plans release of commercial platform in 2026
Nautilus Biotechnology has laid off about 16% of its workforce, reducing its headcount to 133 employees and helping provide a cash runway that extends into 2027.
Nautilus Biotechnology Earnings Call Transcript: Q4 2024
Platform launch delayed to late 2026 to optimize performance, with early access for tau proteoform studies in 2025. FY 2024 net loss increased 11% to $70.8M, and a 16% workforce reduction extends cash runway through 2027.
Nautilus Biotechnology Transcript: Guggenheim Inaugural Global Healthcare Innovation Conference
A novel proteomics platform is set to launch in late 2025, offering unprecedented sensitivity and scale for protein analysis, with early access programs targeting key opinion leaders and pharma partners. Financial discipline has preserved significant cash runway, and leadership experience supports ambitious growth plans.
Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research's Distinguished Investigator Award
Dr. Mallick to be inducted into the Academy for Radiology and Biomedical Imaging Research's esteemed Council of Distinguished Investigators for his outstanding contributions to medical imaging Dr. Mal...
Nautilus Biotechnology to Participate in the Inaugural Guggenheim Healthcare Conference
SEATTLE, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company wil...
Nautilus Biotechnology Earnings Call Transcript: Q3 2024
Q3 2024 saw strong progress in proteoform detection and platform integration, though broad-scale milestones lagged. Operating expenses remained flat, cash runway extends into 2027, and commercial launch is still targeted for late 2025, with early proteoform collaborations planned.
Nautilus Biotechnology Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference
The platform aims to revolutionize proteomics by enabling comprehensive, high-sensitivity protein analysis using PrISM technology, with a user-friendly workflow and cloud-based data management. Launch is targeted for 2025, supported by strong financial discipline and ongoing collaborations.